• Differentiate the clinical profiles of current and emerging immunotherapy agents for the management of HCC
• Analyze clinical trial data related to the use of immunotherapy agents in combination and succession with interventional techniques for HCC
• Advise clinical colleagues on immunotherapy treatment as part of the multidisciplinary HCC cancer treatment team

FACULTY
Ben George, MD
William F. Stapp Endowed Chair
Medical Director, Clinical Trials Office
Associate Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Amanda Smolock, MD
Assistant Professor
Department of Radiology
Medical College of Wisconsin
Milwaukee, Wisconsin

PLANNING COMMITTEE
Ben George, MD
William F. Stapp Endowed Chair
Medical Director, Clinical Trials Office
Associate Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Amanda Smolock, MD
Assistant Professor
Department of Radiology
Medical College of Wisconsin
Milwaukee, Wisconsin

Bruno Odisio, MD
Associate Professor
Co-director of Research at the Department of Interventional Radiology
Division of Diagnostic Imaging
MD Anderson Cancer Center
Houston, Texas

Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, Connecticut

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and Society for Interventional Oncology (SIO). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physicians

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The France Foundation designates this activity for 1.0 nursing contact hour.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and Society for Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from AstraZeneca.

The France Foundation and Society for Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Society for Interventional Oncology and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission